breyanzi
bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastic agents - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.
jinyingzi peifangkeli powder
tianjiang - powder
jinyinhua peifangkeli powder
tianjiang - powder
jinyingzi yifang
top 1 wellness (s) international group pte. ltd. - granules (internal use)
jinyingzi peifangkeli tianjiang
science arts co pte ltd - powders (internal use)
jinyinhua yifang
top 1 wellness (s) international group pte. ltd. - granules (internal use)
jinyinhua formula granule 999
sinchong meheco ltd - granules (internal use)
jinyinhua peifangkeli tianjiang
science arts co pte ltd - powders (internal use)
mijinyingzi yifang
top 1 wellness (s) international group pte. ltd. - granules (internal use)